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Maternal primary and non-primary cytomegalovirus (CMV) infection during pregnancy
can result in in utero transmission to the developing fetus. Congenital CMV (cCMV) can
result in significant morbidity, mortality or long-term sequelae, including sensorineural
hearing loss, the most common sequela. As a leading cause of congenital infections
worldwide, cCMV infection meets many of the criteria for screening. However, currently
there are no universal programs that offer maternal or neonatal screening to identify
infected mothers and infants, no vaccines to prevent infection, and no efficacious and
safe therapies available for the treatment of maternal or fetal CMV infection. Data has
shown that there are several maternal and neonatal screening strategies, and diagnostic
methodologies, that allow the identification of those at risk of developing sequelae and
adequately detect cCMV. Nevertheless, many questions remain unanswered in this field.
Well-designed clinical trials to address several facets of CMV treatment (in pregnant
women, CMV-infected fetuses and both symptomatic and asymptomatic neonates and
children) are required. Prevention (vaccines), biology and transmission factors associated
with non-primary CMV, and the cost-effectiveness of universal screening, all demand
further exploration to fully realize the ultimate goal of preventing cCMV. In the meantime,
prevention of primary infection during pregnancy should be championed to all by means
of hygiene education.
Keywords: cytomegalovirus, neonatal screening, prenatal diagnosis, clinical laboratory techniques, congenital
CMV, pregnancy, maternal screening
INTRODUCTION
Maternal primary and non-primary infection (exogenous reinfection with a different strain or
endogenous viral reactivation) of cytomegalovirus (CMV) during pregnancy can result in in utero
transmission to the fetus (1). Infants can be categorized as symptomatic or asymptomatic based on
clinical symptoms/signs (Table 1) (2). Approximately 11% of live-born infants born with congenital
CMV (cCMV) have abnormal clinical findings at birth (symptomatic) (3). Infants can experience
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TABLE 1 | Possible signs and symptoms in children with congenital CMV
(reproduced from Luck et al.).
CLINICALLY DETECTABLE SYMPTOMS/SIGNS
Physical examination
Small for gestational age (birth weight < −2 standard deviations for
gestational age)
Microcephaly (head circumference < −2 standard deviations for gestational age)
Petechiae or purpura (usually found within hours of birth and persist for
several weeks)
Blueberry muffin rash (intra dermal hematopoiesis)
Jaundicea
Hepatomegaly
Splenomegaly
Neurologic physical examination
Microcephaly (head circumference < −2 standard deviations for gestational age)
Neurologic signs (lethargy, hypotonia, seizures, poor sucking reflex)
ABNORMALITIES DETECTED INCIDENTALLY OR THROUGH
SUBSEQUENT INVESTIGATION/SPECIALIST EXAMINATION
Laboratory results
Anemia
Thrombocytopenia (occurs in the first week but platelets often increase
spontaneously after the second week)
Leukopenia, isolated neutropenia
Elevated liver enzymes (alanine aminotransferase/aspartate aminotransferase)
Conjugated hyperbilirubinemia
Cerebrospinal fluid
Abnormal cerebral fluid indices, positive CMV DNA
Neuroimaging
Calcifications, periventricular cysts, ventricular dilatation, subependymal
pseudocysts, germinolytic cysts, white matter abnormalities, cortical atrophy,
migration disorders, cerebellar hypoplasia, lenticulostriatal vasculopathy
Hearing test
Sensorineural hearing loss uni- or bilaterally
Visual examination
Chorioretinitis, retinal hemorrhage, optic atrophy, strabismus, cataracts
CMV, cytomegalovirus.
aCMV-associated jaundice can be present at the first day after birth and usually persists
longer than physiologic jaundice.
substantial morbidity, mortality, and long-term sequelae,
including sensorineural hearing loss (SNHL), the most common
sequela (4, 5). Infants without symptoms at birth are also
reported to be at risk of developing long-term hearing loss
(6). As a leading cause of congenital infections worldwide (7),
cCMV infection meets many of the criteria for screening: it is
clinically important, well defined and prevalent (4). Nevertheless,
neither universal antenatal screening for CMV during pregnancy
nor universal neonatal screening is routinely recommended
(8) and there remain several challenges that impede their
implementation. Roche Centralised and Point of Care Solutions
and Roche Molecular Diagnostics convened a group of CMV
experts (microbiologists, virologists, and clinicians) to discuss
and offer strategies to address these barriers and knowledge gaps.
This paper provides an overview of those discussions and is a
Abbreviations: cCMV, Congenital cytomegalovirus; CMV, Cytomegalovirus;
DBS, dried blood spots; IgG, Immunoglobulin G; IgM, Immunoglobulin M;
MRI, magnetic resonance imaging; PCR, polymerase chain reaction; SNHL,
Sensorineural hearing loss.
narrative review of serologic and viral nucleic acid screening
and diagnostics in the context of maternal, fetal and neonatal
CMV infection.
MATERNAL CMV SCREENING
CMV screening is offered to some pregnant women in parts
of Europe, Israel, Australia and the USA in the setting
of population-based studies, and independently of nationally
endorsed screening programs (9). However, universal antenatal
screening for CMV is not routinely recommended (8). Reasons
not to screen include the absence of medication to prevent
transmission and the difficulty of predicting sequelae (10).
The introduction of routine testing for CMV in pregnant
women has several implications. Despite the difficulties
mentioned above, the most important benefit of screening would
be to identify fetuses at risk of developing sequelae.
Maternal screening, ideally early in the first trimester, would
also identify those who were CMV-seronegative and thus allow
information to be provided regarding hygiene and behavioral
measures to prevent CMV infection. Evidence has shown that
intervention based on the identification and hygiene counseling
of CMV-seronegative pregnant women significantly prevents
maternal infection (11). Hygiene counseling may also provide (as
yet unproven) benefits for those who are seropositive.
During early pregnancy, repeat serologic screening with
CMV-specific immunoglobulin G (IgG) and -M (IgM) antibodies
of previously seronegative pregnant women at the end of the first
trimester (or until week 20) would identify maternal primary
CMV infection. Although there are no universally accepted
guidelines, testing before 18–20 weeks of pregnancy is reasonable
in order to identify late seroconversion at the end of the first
trimester and implement fetal investigations. In the event of
seroconversion, parents should be informed of the risk of vertical
transmission [32% (3)] and the possible consequences.
Other strategies that could be put in place include maternal
screening at the first prenatal visit and at birth, and neonatal
screening at birth for those whose mothers tested seropositive,
with diagnosis of the neonate by saliva or urine CMV DNA
detection. Previously, this approach to targeted testing detected
82% of all cCMV infections (12). Notably, this study utilized
culture for diagnosis; the detection rate is likely to be improved
with polymerase chain reaction (PCR). This approach may be
more cost-effective than screening all children.
However, screening tests do not identify which mothers will
transmit the virus (13). Moreover, there are no surrogate markers
to predict whether infection in the infant will lead to long-
term sequelae.
Lastly, there are also risks for the mother associated with
maternal screening for CMV that include the stress of having
extra tests, the potential for unnecessary terminations (14), the
potential risk of miscarriage or stillbirth from confirmatory
amniocentesis [inversely correlated to skill/experience of
operator (15)], and the cost. The challenge is in providing
women with choice and information in the context of
population-based economics.
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Serologic and Molecular Testing for
Maternal CMV Infection
Primary infections can be identified by serologic testing. During
pregnancy, IgG and IgM serology is the preferred option;
IgG avidity testing should be used only if CMV-specific
IgM antibodies are positive. Many laboratories consider IgM-
positive results, in combination with IgG avidity results, to
discriminate between primary and non-primary CMV infections
(16). Low CMV IgG avidity indicates primary infection within
the preceding 3–4 months, with an increased risk of intrauterine
transmission to the fetus (17).
CMV-specific serology testing is most useful in the first
trimester due to the increased severity of disease when primary
infection occurs during the embryonic or early fetal period (18).
Quantitative IgG testing is helpful to detect seroconversion and
the stage of infection. Low levels of CMV-IgG antibodies in
maternal serum samples present challenges for the clinician:
low IgG levels can be associated with both a true positive or a
false-positive result (19), so clear guidelines are needed for the
appropriate interpretation of serology results.
All serologic kits vary considerably in their accuracy of the
“low” range of IgG values; a very low value in one test may
be negative using a different test. CMV-IgG avidity testing
should not be performed on serum samples with low IgG levels
as these can give inappropriate IgG avidity results (20). An
incorrect classification of primary CMV infection can lead to
inappropriate management. Finally, maternal serology screening
can be falsely reassuring as non-primary maternal infections will
not be recognized: in Europe, this represents around 50% of all
cCMV cases (21, 22).
The new WHO standard (23) was established for the
calibration of anti-CMV IgG diagnostic kits with quantitative test
interpretation and as an aid in the interpretation of serologic
results in the framework of different assays, platforms, and
clinical settings. The CMV standard could be of value, although
in other settings such as rubella or toxoplasmosis screening,
the use of a standard for calibrating IgG assays has proven
to be suboptimal (24, 25). An algorithm for dealing with low
positive IgG samples may be more useful than a WHO standard.
In particular, in the absence of a gold standard method, an
equivocal IgG serologic assay result in a pregnant woman
should be considered negative. This strategy will ensure that
these women are assigned to the highest CMV risk group for
pregnancy outcome.
The value of viral DNA detection and quantification in
blood, saliva, or urine to help determine the timing of maternal
infection, or to estimate the risk of fetal transmission, is not
yet established. Notably, two studies have demonstrated that
persisting levels of maternal DNAemia during primary CMV
infection at the moment of amniocentesis correlate with a high
risk of CMV transmission to the fetus (26, 27), whilst one other
study has shown that the presence of CMV DNA in maternal
urine and maternal blood correlated with transmission of CMV
to offspring (28).
Prenatal Diagnosis of Fetal CMV Infection
Ultrasound imaging has poor sensitivity in diagnosing fetal CMV
infection (29) but is a useful tool to predict the prognosis of
fetal infection. Diagnosis of fetal CMV infection by CMV PCR
in the amniotic fluid can be made with high sensitivity and
specificity by amniocentesis after 20–21 weeks’ gestation (30)
[and >8 weeks after estimated maternal seroconversion (31)]
and is the best available prenatal diagnostic tool (32). When
the diagnosis of fetal infection is by way of amniocentesis, the
prognostic evaluation of fetal infection relies on imaging using
a combination of ultrasound and cerebral magnetic resonance
imaging (MRI). Several studies have identified a residual risk
of hearing loss at birth when imaging (ultrasound and/or MRI)
examination was considered to be normal (33–38).
NEONATAL CMV SCREENING
Neonatal CMV screening would enable early detection of
cCMV (following primary and non-primary maternal infection),
but universal neonatal screening for CMV is currently not
recommended by any public health body. Data from Uematsu
and colleagues emphasize that without neonatal screening some
infected neonates that develop neurological sequelae may go
unrecognized (39).
Although universal screening is not performed, targeted
screening of newborns who fail the neonatal hearing test has been
implemented in some hospitals and states in the USA (40, 41).
In the UK, Belgium and Australia, targeted testing of infants
who were referred for further audiological testing (after failing
the routine hearing screening) has also been trialed with some
success (42–44). This combination of targeted newborn screening
and early detection and interventions is likely to benefit children
with cCMV (45).
Additionally, the costs associated with targeted neonatal
screening look favorable compared with other screening
programs (46, 47). However, this targeted approach would miss
those CMV-positive infants who pass the newborn hearing test
but are still at risk for late-onset SNHL (40, 48). In one study,
43% of infants with CMV-related SNHL in the neonatal period
and cCMV infants who are at risk for late-onset SNHL were not
identified by newborn hearing screening (49).
There are risks associated with neonatal screening, such as
the potential for parental anxiety while waiting for confirmatory
testing results. In addition, there may be anxiety related to
the extended period of audiological monitoring that a cCMV-
positive infant must undergo [up to 6 years (2, 50, 51)]. Most
cCMV infections are asymptomatic and do not present a risk
for the onset of late sequelae (5). Recent data demonstrated that
primary maternal infections before the 14th week of pregnancy,
the presence of a disseminated infection at birth, and imaging
abnormalities in the neonate were risk factors for SNHL (52).
This is a step toward the development of neonatal predictive
markers that can be used to identify those at high risk of
developing sequelae.
Diagnosis and Screening of Neonatal
Infection
Testing is recommended for those who have any condition
that might be indicative of intrauterine CMV infection (2).
Traditionally, viral isolation and culture from urine or saliva was
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the standard for diagnosing cCMV infection (53). Since PCR
exhibits high sensitivity (54, 55), this is now the preferred option.
False-positive tests have been reported for saliva, and therefore
any positive saliva result should be confirmed by CMV detection
in urine (21).
It should be noted that if the diagnosis is made after the first 2–
3 weeks of life (2, 9), infectionmay have been postnatally acquired
and attributable to infected breast milk from a seropositive
mother (56), rather than cCMV. In this instance, congenital
infection must be confirmed by detection of CMV from a sample
taken at birth.
Saliva can be used to screen for cCMV; however, as this
specimen type is not routinely collected from neonates, a change
in infrastructure would be required before this could be rolled out
on a large scale. As such, alternative technologies for universal
screening are currently under evaluation. Due to widespread
utilization in neonatal screening for other conditions, there has
been much interest in using dried blood spots (DBS) taken
at birth for CMV screening. However, screening DBS is less
sensitive than PCR testing of saliva, with sensitivity ranging
between 28 and 100% (57), and is contingent upon the method
of extraction and DNA amplification and the patient group
selected. The recent standardization of viral DNA extraction and
innovative PCR techniques has led to improved sensitivity of
DBS screening to around 80% (58). A potential limitation in the
use of DBS is that only 80–90% of congenitally infected infants
have detectable CMV in their blood soon after birth (59, 60).
Despite this, the sensitivity of DBS screening has been shown to
adequately detect those most at risk of developing SNHL (61).
Stored DBS can be used to diagnose cCMV retrospectively
(2). In some countries (e.g., Germany), the use of DBS for
retrospective diagnosis or screening of newborns is hampered
by the destruction of samples after 3 months (62) due to data
protection requirements. Thus, for certain countries, regulatory
changes may be necessary to allow long-term storage and use in
this context.
WHAT ARE THE GAPS IN OUR
UNDERSTANDING?
Although significant advancements have been made, many
questions remain unanswered in this field (Table 2). Well-
designed clinical trials to address several facets of CMV
treatment (in pregnant women, CMV-infected fetuses and
both symptomatic and asymptomatic neonates and children)
are required. Prevention (vaccines), biology, and transmission
factors associated with non-primary CMV, and the cost-
effectiveness of universal screening, all demand further
exploration to fully realize the ultimate goal of preventing cCMV.
Currently, treatment with immunoglobulins or antiviral
therapy to prevent intrauterine transmission of CMV in pregnant
women with primary CMV infection is not recommended as
studies have not yet conclusively shown a benefit (63–66).
Data from a non-randomized study showed that biweekly
administration of hyperimmunoglobulin until 20 weeks’
gestation successfully prevented maternal-fetal transmission of
TABLE 2 | Studies required to improve the understanding of congenital CMV.
DIAGNOSIS
Non-primary infection
in pregnant women
Identify virologic and immunological markers predictive of
cCMV in women seropositive before pregnancy
Identify virologic and immunological CMV-specific tests
to properly diagnose maternal non-primary infection
in pregnancy
Universal neonatal
screening
Evaluate the performance of CMV PCR in DBS to identify
neonates with sequelae and determine
cost-effectiveness
PREVENTION
Prevention of fetal
transmission in
maternal primary
infection
Randomized controlled studies with new antiviral drugs
Prevention of maternal
infection
Randomized controlled studies of optimal education
methods and efficacy of hygiene measures in general
population
TREATMENT
Treatment of fetal
infection
Randomized controlled studies with new available
antiviral drugs
Treatment of infection
in the neonate
Randomized controlled studies:
– with new antiviral drugs;
– with known antiviral drugs to confirm the effectiveness
of known therapies;
– in asymptomatic babies with no clinical examination
abnormalities at birth (including those developing later
hearing loss);
– to determine the optimal duration and dosage
of treatment
Registries of long-term treatment sequelae
(c)CMV, (congenital) cytomegalovirus; DBS, dried blood spot; PCR, polymerase
chain reaction.
primary infections (65). These data need to be confirmed by
a randomized clinical trial (67); if the results are confirmed,
two-weekly intervals for testing seronegative women would be
necessary. It has been suggested that a study that demonstrates
treatment efficacy resulting in at least a 47% reduction in cCMV
disease would make universal screening and treating for primary
CMV in pregnancy cost-effective (10).
Whilst recent improvements in screening and diagnosis
allow detection of primary CMV infection in pregnancy,
unfortunately treatment options for CMV-infected fetuses and
neonates are limited due to insufficient evidence for safety
and effectiveness. Consequently, routine antiviral therapy to
treat fetal CMV during pregnancy is not recommended (9). In
infants with clinical disease at birth, early intervention with
ganciclovir or valganciclovir can prevent hearing deterioration
and improve developmental outcomes, although both treatments
are associated with neutropenia (68, 69) and other possible
long-term effects (70). Currently, valganciclovir treatment is
recommended based on severity or number of symptoms.
A European expert consensus statement recommends that
treatment with oral valganciclovir (intravenous ganciclovir
under certain circumstances) is only for those with: evidence
of central nervous system disease; evidence of life-threatening
disease, severe single-organ disease or multi-organ involvement;
“moderate” cCMV disease once discussed on a case-by-case basis
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TABLE 3 | Expert panel recommendations for the diagnosis, screening, and
prevention of CMV infection.
RECOMMENDATIONS FOR DIAGNOSIS
Primary infection in pregnant
women
IgG, IgM, IgG avidity if positive IgM and IgG
Non-primary infection in
pregnant women
No tools validated
Fetal infection CMV PCR in amniotic fluid after 20 weeks and
more than 8 weeks after presumed onset of
maternal primary infection
Neonatal infection CMV PCR in saliva or urine collected in the first 3
weeks of life
Retrospective diagnosis in
toddlers with compatible
symptoms
CMV PCR in neonatal DBS
RECOMMENDATIONS FOR SCREENING AND PREVENTION
Primary prevention of
maternal primary infection
Information for pregnant women on cCMV and
application of hygienic measures to prevent
maternal infection
Infection in pregnant women No recommendation for screening
Information for pregnant women on cCMV and
application of hygienic measures to prevent
maternal infection
Universal neonatal screening No recommendation
Targeted testing in neonates
who failed universal hearing
screening
CMV PCR in saliva (if positive, confirm in urine or
by DBS PCR if the infant is > 3 weeks of age)
(c)CMV, (congenital) cytomegalovirus; DBS, dried blood spot; Ig, immunoglobulin; PCR,
polymerase chain reaction.
with a clinician with experience of managing infants with cCMV
(2). The informal International Congenital Cytomegalovirus
Recommendations Group recommend oral valganciclovir
treatment for those neonates with “moderately” to “severely”
symptomatic cCMV disease (9). Further development of
efficacious antivirals with an acceptable safety profile is required.
Letermovir is a new agent approved for use in the prophylaxis
of CMV infection in CMV-seropositive recipients of an
allogeneic hematopoietic stem cell transplant over the age of
18 years (71). A recent case study revealed potential efficacy in
pediatric allogeneic hematopoietic stem cell transplant patients
(72). Further studies are required to determine whether it is safe
and effective for treating those with cCMV.
More asymptomatic infants will be discovered if screening
programs become widespread. Currently, antiviral therapy
for asymptomatic infants is not recommended (2) but, like
symptomatic infants, they are at risk of developing late-onset
sequelae (53). Trials that investigate which interventions are
effective and safe for asymptomatic infants or those with isolated
hearing loss or subtle neuroimaging abnormalities, as well as
older children that develop late-onset hearing loss, are necessary.
Since clinical trials are ongoing (73–75), some of these points
will hopefully be clarified in the next few years and the best
management plan for this population determined.
As well as trials targeting treatment for specific populations,
data on prevention are also required. It is known that natural
infection confers some protection against both horizontal and
vertical transmission (13, 76), therefore the development of an
effective vaccine is feasible. Clinical trials of CMV vaccines
should evaluate protection against cCMV infection (77). Recent
modeling data of a single fictional cohort of 390,000 adolescent
women suggest that vaccination could be cost-effective (78).
In the absence of a vaccine to prevent infection, a greater focus
on education and prevention strategies for cCMV infection are
needed for women intending to become pregnant, those already
pregnant, and healthcare professionals alike. Preconception
screening in those attending a fertility clinic, with resultant
counseling to improve personal hygiene in those who were not
immune to CMV, has shown that hygiene counseling (albeit
in this highly selected cohort) is effective in reducing CMV
exposure (79). In pregnant women, hygiene counseling of CMV-
seronegative pregnant women significantly prevents maternal
infection (11). De Vries and colleagues showed that non-primary
infections account for the majority of CMV-related hearing loss,
suggesting prevention research should encompass all pregnant
women, not just those who are seronegative (80). Therefore, the
current method aimed at preventing transmission of CMV—
education concerning hygienemeasures to be taken around small
children [such as avoiding kissing babies on the mouth, not
sharing cutlery with young children, and hand hygiene after a
diaper change (11)]—should be performed regardless of knowing
the mother’s serostatus. However, in the general population,
there is inadequate evidence to show that education translates
into a decrease in maternal infection (4). Studies assessing the
efficacy of hygiene measures on the prevention of CMV infection
in pregnancy, and resultant cCMV, are necessary in women of
reproductive age and are ongoing in the UK (81).
Clinicians do not know whether a non-primary infection is
a reactivation or an infection with another strain of CMV. This
distinction may be important in understanding the etiology of
CMV disease, thus more research on the role of non-primary
maternal CMV infections in congenital infection is necessary. At
present, there are no tools validated to identify women at risk of
transmitting the virus after a non-primary infection.
Finally, further evidence of cost-effectiveness is required.
Whilst the cost-effectiveness of universal and targeted newborn
cCMV screening programs has been assessed in the UK and
USA (46, 47), and the economic burden of cCMV in the UK
estimated (82), currently there are insufficient cost-benefit data,
which hinders the implementation of screening.
CONCLUSIONS
cCMV infection results in significant consequences for the
infected neonate. Despite this, universal maternal or neonatal
screening for CMV and cCMV is not routinely recommended.
A summary of our current recommendations for diagnosis,
screening, and prevention is provided in Table 3. Presently
there are significant gaps in understanding that prevent the
implementation of universal screening, including insufficient
data on cost-effectiveness and the lack of evidence for safe and
efficacious treatments for those infected. Additionally, further
data on non-primary maternal infection and the risk of cCMV
infection are necessary. In the near future, we are confident that
many aspects related to diagnosis, maternal and fetal therapy, and
active prevention will surely present an improvement and our
recommendations may change. Until then, and in the absence of
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a vaccine, hygiene recommendations to prevent CMV infection
should be made to all pregnant women.
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